Gilead Sciences, Craft Brew Alliance, Capital One Financial, HSBC Holdings and Encore Capital Group highlighted as Zacks Bull

Gilead Sciences, Craft Brew Alliance, Capital One Financial, HSBC Holdings and
      Encore Capital Group highlighted as Zacks Bull and Bear of the Day

PR Newswire

CHICAGO, Sept. 6, 2013

CHICAGO, Sept. 6, 2013 /PRNewswire/ -- Zacks Equity Research highlights Gilead
Sciences (Nasdaq:GILD-Free Report) as the Bull of the Day and Craft Brew
Alliance (Nasdaq:BREW-Free Report) as the Bear of the Day. In addition, Zacks
Equity Research provides analysis ontheCapital One Financial Corp.
(NYSE:COF-Free Report), HSBC Holdings plc (NYSE:HBC-Free Report) and Encore
Capital Group, Inc. (Nasdaq:ECPG-Free Report).


Here is a synopsis of all five stocks:

Bull of the Day:

With the market facing some choppiness as of late, many investors are taking
another look at some of the strong sectors that have been leading the market
for much of 2013. One such segment is undoubtedly biotechnology, as this key
corner of the healthcare world has been a star performer for much of the year.

After all, many biotechnology ETFs have added more than 35% so far this
year—compared to a gain of close to 15% for the S&P 500—and remain well
positioned for further gains to close out 2013 as well.

Yet while a broad sector approach may be one way to target this impressive
corner of the market, looking solely at some of the large caps in the space
may also be an interesting play. That is because these large biotech firms
have actually beaten out their broader ETF counterparts by pretty wide margins
too, suggesting that these large cap firms are leading the way in the
biotechnology world.

One such company that fits this bill is Gilead Sciences (Nasdaq:GILD-Free
Report), a massive nearly $100 billion market cap behemoth in the biotech
space. The firm has already added more than 60% so far this year, and based on
some of GILD's fundamentals, the company could definitely see more gains to
close out 2013 as well.

Gilead is a California-based biopharmaceutical company that seeks to develop
and commercialize therapies for life threatening diseases. The firm currently
has a lineup of products for HIV, liver disease, the flu, respiratory
diseases, among others.

Furthermore, unlike a number of big pharma companies, Gilead has a solid
product pipeline, as a number of drugs are in Phase III, while several more
are in Phase II. Combine this with Gilead's track record of buying out
promising small caps, and the firm could have a long term recipe for success.

Bear of the Day:

Craft beer is taking the U.S. by storm. Many beer drinkers are growing tired
of brews from giants like Anheuser-Buschor MolsonCoorsand are instead looking
at smaller, so-called 'craft brewers' which produce less than six million US
beer barrels a year.

This trend has led to huge stock price increases for the few craft brewer
stocks out there on the market. In fact, the tiny Craft Brew Alliance
(Nasdaq:BREW-Free Report)has seen its price soar by more than 60% so far this
year, easily crushing many of its larger counterparts in the process.

While this Oregon-based brewer may be playing on a strong trend, there is
plenty of reason to believe that it cannot last and that trouble is ahead for
this stock. This is especially apparent when investors consider the recent
earnings history of the firm, and its near term estimate outlook.

While the company does look to have strong double digit growth for the current
year, analysts have been slashing their estimates for the full year and next
year earnings. Estimates for full year earnings have fallen by more than 15%
in the past month while a 10% decline has been seen in the same time frame for
next year's earnings estimates.

If that wasn't enough, the company also has a horrendous track record when it
comes to beating earnings estimates. Three of the last four quarters saw
misses of at least 25%, while an average surprise of -115% was seen over these
last four reports.

The firm isn't exactly a value at these levels either, as the PE comes in at
just under 77, while the PEG is squeaks in below 3.9. These figures suggest
that a lot is riding on the company's growth prospects, but with analysts
cutting their estimates, it may be tough for BREW to live up to the hype.

Additional content:

Capital One Downgraded to Neutral

On Sep 3, 2013, we downgraded our long-term recommendation on Capital One
Financial Corp. (NYSE:COF-Free Report) to Neutral from Outperform due to the
persistent increase in operating expenses. Though the company's second-quarter
results were positive, we are concerned about limited margin growth, exposure
to risky assets, and regulatory pressures.

Why the Downgrade?

Increasing operating expenses remain the primary concern for Capital One.
Though expense control initiatives have helped the company offset higher
credit losses in the past few years, operating expense has still been
continuously increasing.

Moreover, any considerable improvement in Capital One's credit quality seems
unlikely in the near future, given the still sluggish economic recovery. While
the credit performance of the commercial loan portfolio appears to be
stabilizing, net charge-offs and nonperforming loans will likely fluctuate in
the near term due to the present economic instability and acquisition of HSBC
Holdings plc's (NYSE:HBC-Free Report) U.S. credit card business.

Nevertheless, Capital One reported robust second-quarter earnings which came
ahead of the Zacks Consensus Estimate. Results were driven by enhanced top
line, partially offset by a rise in operating expenses. Moreover, in May 2013,
the company increased its dividend by 500% to $0.30 per share.

The Zacks Consensus Estimate for 2013 advanced 4.0% to $6.82 per share over
the last 60 days. Further, for 2014, the Zacks Consensus Estimate increased
1.6% to $6.80 per share over the same time period. Capital One currently
carries a Zacks Rank #3 (Hold).

Other Stocks Worth Considering

Some better performing banks include Encore Capital Group, Inc.
(Nasdaq:ECPG-Free Report), which carries a Zacks Rank #2 (Buy).

Get today's Zacks #1 Stock of the Day with your free subscription to Profit
from the Pros newsletter:

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Click here to subscribe to this
free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the

Get the full Report on GILD - FREE

Get the full Report on BREW - FREE

Get the full Report on COF - FREE

Get the full Report on HBC - FREE

Get the full Report on ECPG - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339 provides investment resources and informs you of these resources,
which you may choose to use in making your own investment decisions. Zacks is
providing information on this resource to you subject to the Zacks "Terms and
Conditions of Service" disclaimer.

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.